Marjan Sadeghi

Dr. Marjan Sadeghi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Toxicon
Verified
Journal Article
Open access
KDKhashayar Dashtipour
Khashayar Dashtipour
MSMarjan Sadeghi
Marjan Sadeghi
PCPhilip David Charles
Philip David Charles
SMShyamal Mehta
Shyamal Mehta
HFHubert H. Fernandez
Hubert H. Fernandez
Joseph JankovicJoseph Jankovic
Joseph Jankovic
Anterocollis (AC) and retrocollis (RC) are less common cervical dystonia (CD) subtypes that are often under-represented in CD clinical trials. Herein we describe real-world demographics, disease characteristics, and treatment response to onabotulinumtoxinA (onabotA) in AC or RC patients from an observational, multicenter, prospective registry, CD PROBE. After three onabotA treatments, outcomes (CDIP-58, PGIC, CGIC, CD severity, TWSTRS) in patients with predominant AC or RC were compared to torticollis (TC) and all CD subtypes combined. The mean dosages at each treatment ranged from 153.5 to 195.4 U (AC) to 184.0-213.4 U (RC). After treatment, AC and RC patients reported improvements in the CDIP-58. "Much" or "very much improved" on PGIC and CGIC was reported by AC patients (n = 11/23, 48%) and clinicians (n = 14/23, 61%); and by RC patients (n = 14/24, 58%) and clinicians (n = 19/24, 83%). The mean total TWSTRS decreased from 45.7 (n = 59) to 36.1 (n = 23, 21.0% improvement) for AC patients and from 40.1 (n = 55) to 31.6 (n = 23, 21.2% improvement) for RC patients; the proportion of AC and RC patients with severe CD decreased. Outcomes for AC and RC were generally consistent with those for TC and all subtypes combined. Dysphagia was reported in 4/59 (6.8%) of AC patients (one serious), 7/55 (12.7%) of RC patients (none serious), 29/494 (5.9%) of TC patients (none serious), and 64/1012 (6.3%) of all CD patients (two serious). No new safety signals were identified. In conclusion, treatment with onabotA may relieve CD symptoms in some patients with AC and RC, consistent with results for other CD subtypes and the known safety profile of onabotA for the treatment of CD.

21 January 2024 in Toxicon
Verified
Journal Article
Closed access
KDKhashayar Dashtipour
Khashayar Dashtipour
MSMarjan Sadeghi
Marjan Sadeghi
MHMaria Heath
Maria Heath
ARAndrew Rava
Andrew Rava
JLJinjie Liu
Jinjie Liu
JLJae Lee
Jae Lee

19 March 2025 in Toxins
Verified
Journal Article
Open access
PDF file
RBRichard L Barbano
Richard L Barbano
Bahman JabbariBahman Jabbari
Bahman Jabbari
MSMarjan Sadeghi
Marjan Sadeghi
AUAhunna Ukah Ukah
Ahunna Ukah Ukah
EYEmma Yue
Emma Yue
DSDavid Swope
David Swope
Dysphagia is prevalent in patients with cervical dystonia (CD) and is a potential adverse event in patients treated with botulinum neurotoxin (BoNT) for CD. Real-world studies may provide a better understanding of the incidence and potential risk factors of dysphagia after BoNT administration. This retrospective cohort study used longitudinal patient-level data from Optum’s de-identified Market Clarity Data to evaluate rates of dysphagia in patients with CD exposed and unexposed to BoNT. Patients ≥18 years of age with ≥2 CD diagnoses ≥30 days apart during the study period (1 January 2017–30 September 2021) who had ≥180 days of continuous health plan enrollment prior to the cohort entry date (first CD diagnosis) were included. Overall, the mean (SD) age of all CD patients (Cohort 1; N = 81,884) was 54.00 (16.21) years, and they were mostly female (67.9%) and white (76.96%). BoNT-Exposed patients (Cohort 2; N = 19,244) had a higher incidence of dysphagia (16.3%) and comorbid conditions when compared with BoNT-Unexposed patients (Cohort 3; N = 61,154 [12.1%]). Overall, patients with pre-existing dysphagia, other dystonias, and comorbid neurologic conditions at baseline also had higher proportions of dysphagia. This real-world analysis indicates that comorbid conditions predispose patients with CD to a greater dysphagia risk during treatment.

16 January 2024 in Toxicon
Verified
Journal Article
Closed access
MSMarjan Sadeghi
Marjan Sadeghi
AUAhunna Ukah
Ahunna Ukah
EYEmma Xiaomeng Yue
Emma Xiaomeng Yue
KIKim Becker Ifantides
Kim Becker Ifantides
NHNuo-Yu Huang
Nuo-Yu Huang
RBRichard L. Barbano
Richard L. Barbano